Product Description
This second-generation γ-secretase modulator is in development for the treatment of Alzheimer's disease. The rationale is that, unlike γ-secretase inhibitors, which inhibit the enzyme complex outright, modulators shift APP cleavage toward production of shorter Aβ peptides and away from production of longer, aggregation-prone peptides such as Aβ42 and Aβ43, while sparing γ-secretase's physiological cleavages of substrates such as notch. (Sourced from: https://www.alzforum.org/therapeutics/nivegacetor)
Mechanisms of Action: G-Secretase Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Arthrogryposis|Alzheimer Disease
Phase 0: Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06996730 |
API-2 | P3 |
Not yet recruiting |
Alzheimer Disease|Arthrogryposis |
2030-06-01 |
2025-08-05 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/14/2024 |
News Article |
New Alzheimer's prevention trial receives $74.5 million NIH grant |